Renalytix Plc
RNLX · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $522 | $586 | $535 | $709 |
| % Growth | -10.9% | 9.5% | -24.5% | – |
| Cost of Goods Sold | $422 | $550 | $601 | $480 |
| Gross Profit | $100 | $36 | -$66 | $229 |
| % Margin | 19.2% | 6.1% | -12.3% | 32.3% |
| R&D Expenses | $921 | $1,062 | $2,216 | $3,225 |
| G&A Expenses | $3,271 | $4,499 | $7,095 | $2,207 |
| SG&A Expenses | $3,271 | $4,499 | $3,854 | $5,339 |
| Sales & Mktg Exp. | $0 | $0 | -$3,241 | $3,132 |
| Other Operating Expenses | $1 | $37 | -$49 | $0 |
| Operating Expenses | $4,193 | $5,561 | $6,070 | $8,564 |
| Operating Income | -$4,093 | -$5,525 | -$6,136 | -$8,335 |
| % Margin | -784.1% | -942.8% | -1,146.9% | -1,175.6% |
| Other Income/Exp. Net | -$633 | -$1,549 | -$1,607 | -$793 |
| Pre-Tax Income | -$4,726 | -$7,074 | -$7,743 | -$9,128 |
| Tax Expense | $2 | $0 | $0 | $4 |
| Net Income | -$4,728 | -$7,074 | -$7,743 | -$8,485 |
| % Margin | -905.7% | -1,207.2% | -1,447.3% | -1,196.8% |
| EPS | -0.08 | -0.1 | -0.16 | -0.17 |
| % Growth | 20% | 37.5% | 5.9% | – |
| EPS Diluted | -0.08 | -0.1 | -0.16 | -0.18 |
| Weighted Avg Shares Out | 52,849 | 69,080 | 48,394 | 47,139 |
| Weighted Avg Shares Out Dil | 52,849 | 69,080 | 48,827 | 48,634 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $60 | $60 | $69 | $108 |
| EBITDA | -$4,032 | -$5,465 | -$6,067 | -$8,878 |
| % Margin | -772.4% | -932.6% | -1,134% | -1,252.2% |